• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination Therapy With Pulmonary Vasodilatation and JAK2 Inhibition for Pulmonary Hypertension With Polycythemia Vera.

作者信息

Momose Riichi, Inami Takumi, Takeuchi Kaori, Kikuchi Hanako, Goda Ayumi, Kohno Takashi, Soejima Kyoko, Takayama Nobuyuki, Satoh Toru

机构信息

Kyorin University School of Medicine, Tokyo, Japan.

Department of Cardiovascular Medicine, Kyorin University School of Medicine, Tokyo, Japan.

出版信息

CJC Open. 2022 Nov 13;5(1):90-92. doi: 10.1016/j.cjco.2022.11.007. eCollection 2023 Jan.

DOI:10.1016/j.cjco.2022.11.007
PMID:36700179
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9869346/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed91/9869346/24f6f60ef873/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed91/9869346/24f6f60ef873/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed91/9869346/24f6f60ef873/gr1.jpg

相似文献

1
Combination Therapy With Pulmonary Vasodilatation and JAK2 Inhibition for Pulmonary Hypertension With Polycythemia Vera.肺动脉扩张与JAK2抑制联合治疗真性红细胞增多症相关性肺动脉高压
CJC Open. 2022 Nov 13;5(1):90-92. doi: 10.1016/j.cjco.2022.11.007. eCollection 2023 Jan.
2
Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.真性红细胞增多症、原发性骨髓纤维化和原发性血小板增多症中的细胞遗传学、JAK2和MPL突变
Rev Bras Hematol Hemoter. 2011;33(6):417-24. doi: 10.5581/1516-8484.20110116.
3
Megakaryocytic morphology and clinical parameters in essential thrombocythemia, polycythemia vera, and primary myelofibrosis with and without JAK2 V617F.真性红细胞增多症、原发性血小板增多症以及原发性骨髓纤维化伴或不伴JAK2 V617F突变时的巨核细胞形态及临床参数
Arch Pathol Lab Med. 2014 Sep;138(9):1203-9. doi: 10.5858/arpa.2013-0018-OA.
4
An inhibitor of Janus kinase 2 prevents polycythemia in mice.一种Janus激酶2抑制剂可预防小鼠的红细胞增多症。
Biochem Pharmacol. 2009 Aug 15;78(4):382-9. doi: 10.1016/j.bcp.2009.04.025. Epub 2009 May 3.
5
[Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].[JAK2V617F突变在慢性骨髓增殖性肿瘤患者中的意义]
Orv Hetil. 2011 Nov 6;152(45):1795-803. doi: 10.1556/OH.2011.29226.
6
Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series.真性红细胞增多症所致的肺髓外造血与肺动脉高压：病例系列
Pulm Circ. 2017 Mar 10;7(1):261-267. doi: 10.1177/2045893217702064. eCollection 2017 Mar.
7
Extent of hematopoietic involvement by TET2 mutations in JAK2V⁶¹⁷F polycythemia vera.TET2 突变在 JAK2V⁶¹⁷F 真性红细胞增多症中对造血系统影响的程度。
Haematologica. 2011 May;96(5):775-8. doi: 10.3324/haematol.2010.029678. Epub 2011 Jan 27.
8
Pulmonary hypertension in polycythemia vera.真性红细胞增多症中的肺动脉高压。
Am J Hematol. 1994 Nov;47(3):242-4. doi: 10.1002/ajh.2830470320.
9
Two clinical phenotypes in polycythemia vera.真性红细胞增多症的两种临床表型。
N Engl J Med. 2014 Aug 28;371(9):808-17. doi: 10.1056/NEJMoa1403141.
10
Diagnostic Performance of Erythropoietin Levels in Polycythemia Vera: Experience at a Comprehensive Cancer Center.真性红细胞增多症中红细胞生成素水平的诊断性能：综合癌症中心的经验。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):224-229. doi: 10.1016/j.clml.2020.11.002. Epub 2020 Nov 5.

引用本文的文献

1
High pulmonary hypertension risk by echocardiogram shortens survival in polycythemia vera.超声心动图显示肺动脉高压风险高会缩短真性红细胞增多症患者的生存期。
Blood Adv. 2025 Mar 25;9(6):1320-1329. doi: 10.1182/bloodadvances.2024013970.
2
Exploring new horizons: angiotensin II, angiotensin II type 1 receptor, and renal outer medullary potassium channel interaction in distal convoluted tubule.探索新领域：血管紧张素II、血管紧张素II 1型受体与远端曲小管中肾外髓质钾通道的相互作用
Kidney Res Clin Pract. 2025 May;44(3):461-480. doi: 10.23876/j.krcp.24.023. Epub 2024 Sep 19.

本文引用的文献

1
Evaluation of hemodynamic parameters among patients with myeloproliferative neoplasms and suspected pulmonary hypertension.评估骨髓增殖性肿瘤伴疑似肺动脉高压患者的血液动力学参数。
Leuk Lymphoma. 2021 Jun;62(6):1458-1465. doi: 10.1080/10428194.2020.1864351. Epub 2021 Jan 25.
2
Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension.右心功能障碍对骨髓增殖性肿瘤相关肺动脉高压患者的附加价值。
J Am Soc Echocardiogr. 2019 Dec;32(12):1574-1585. doi: 10.1016/j.echo.2019.07.010. Epub 2019 Oct 3.
3
Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera.
真性红细胞增多症患者中与肺静脉闭塞性疾病相关的肺动脉高压
Intern Med. 2017 Sep 15;56(18):2487-2492. doi: 10.2169/internalmedicine.8629-16. Epub 2017 Aug 21.
4
Pulmonary hypertension in patients with chronic myeloproliferative disorders.慢性骨髓增殖性疾病患者的肺动脉高压
Eur Respir Rev. 2015 Sep;24(137):400-10. doi: 10.1183/16000617.0041-2015.
5
Ruxolitinib leads to improvement of pulmonary hypertension in patients with myelofibrosis.芦可替尼可改善骨髓纤维化患者的肺动脉高压。
Leukemia. 2014 Jul;28(7):1486-93. doi: 10.1038/leu.2014.5. Epub 2014 Jan 10.